Pathophysiology and organ damage in anaphylaxis

Anaphylaxis and Hypersensitivity Reactions

Volumn , Issue , 2011, Pages 33-46

  Kemp, Stephen F ^a   Lockey, Richard F ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Anaphylaxis; Pathophysiology; Severe allergic reactions; Systemic allergic reactions

Indexed keywords

EID: 79960835526     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60327-951-2_3     Document Type: Chapter

References (90)

1. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2006;117:391-397.
2. Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 2002;110:341-348.
3. Simons FER, Sampson HA. Anaphylaxis epidemic: fact or fiction? J Allergy Clin Immunol 2008;122:1166-1168.
4. Pumphrey, RS. Fatal anaphylaxis in the UK, 1992-2001. Novartis Found Symp 2004;257:116-128.
5. Johansson SGO, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832-836.
6. Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA, Lachmann PJ, eds. Clinical Aspects of Immunology, 3rd ed. Oxford, England: Blackwell; 1975:761-781.
7. Sell S. Immunopathology. In: Rich RR, Fleisher TA, Schwartz BD, et al., eds. Clinical Immunology: Principles and Practice. St. Louis, Mo.: Mosby; 1996:449-477.
8. Finkelman FD. Anaphylaxis: lessons from mouse models. J Allergy Clin Immunol 2007;120:506-515.
9. Strait RT, Morris SC, Finkelman FD. IgG blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interruption and Fcγ(gamma)RIIb cross-linking. J Clin Invest 2006;116:833-841.
10. Shibamoto T, Liu W, Cui S, et al. PAF, rather than histamine, participates in mouse anaphylactic hypotension. Pharmacology 2008;82:114-120.
11. Yokoi H, Myers A, Matsumoto K, et al. Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells. Allergy 2006;61:769-776.
12. Olivera A, Mizugishi K, Tikhonova A, et al. The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity 2007;26:287-297.
13. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98:1315-1324.
14. Stallmach A, Giese T, Schmidt C, et al. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab-report of a case. Eur J Gastroenterol Hepatol 2004;16:627-630.
15. Hod EA, Sokol SA, Zimring JC, Spitalnik SL. Hypothesis: hemolytic transfusion reactions represent an alternative type of anaphylaxis. Int J Clin Exp Pathol 2009;2:71-82.
16. Cox L, Platts-Mills TAE, Finegold I, et al. American academy of allergy, asthma & immunology/American college of allergy, asthma and immunology joint task force report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007;120:1373-1377.
17. Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 2006;96:624-627.
18. Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxis. Blood 2007;110:2331-2333.
19. Lieberman P. Anaphylaxis and anaphylactoid reactions. In: Adkinson NF Jr, Yunginger JW, Busse WW, et al., eds. Middleton's Allergy: Principles and Practice, 6th ed. St. Louis, Mo.: Mosby Year Book; 2003:1497-1522.
20. Ono E, Taniguchi M, Mita H, et al. Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis. Clin Exp Allergy 2009;39:72-80.
21. Kinn JW, Bache RJ. Effect of platelet activation on coronary collateral blood flow. Circulation 1998;98:1431-1437.
22. Choi IH, Ha T Y, Lee DG, et al. Occurrence of disseminated intravascular coagulation (DIC) in active systemic anaphylaxis: role of platelet-activating factor. Clin Exp Immunol 1995;100:390-394.
23. Vadas P, Gold M, Perelman B, Liss GM, Lack G, Blyth T, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008;358:28-35.
24. Lieberman P. Biphasic anaphylactic reactions. Ann Allergy Asthma Immunol 2005;95:217-228.
25. Pushparaj PN, Tay HK, H'ng SC, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci USA 2009;106:9773-9778.
26. Goetzl EJ, Wasserman SI, Austin KF. Eosinophil polymorphonuclear leukocyte function in immediate hypersensitivity. Arch Pathol 1975;99:1-4.
27. Erjefält JS, Korsgren M, Malm-Erjefält M, et al. Acute allergic responses induce a prompt luminal entry of airway tissue eosinophils. Am J Respir Cell Mol Biol 2003;29:439-448.
28. Kaliner M, Sigler R, Summers R, Shelhamer JH. Effects of infused histamine: analysis of the effects of H-1 and H-2 receptor antagonists on cardiovascular and pulmonary responses. J Allergy Clin Immunol 1981;68:365-371.
29. Chrusch C, Sharma S, Unruh H, et al. Histamine H3 receptor blockade improves cardiac function in canine anaphylaxis. Am J Respir Crit Care Med 1999;160:142-149.
30. Schwartz LB. Effector cells of anaphylaxis: mast cells and basophils. Novartis Found Symp 2004;257:65-74.
31. Yunginger JW, Nelson DR, Squillace DL, et al. Laboratory investigations of death due to anaphylaxis. J Forensic Sci 1991;36:857-865.
32. Lin RY, Schwartz LB, Curry A, et al. Histamine and tryptase levels in patients with acute allergic reactions: an emergency department-based study. J Allergy Clin Immunol 2000;106:65-71.
33. Smith PL, Kagey-Sobotka A, Bleecker ER, et al. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980;66:1072-1080.
34. Pumphrey RS, Roberts IS. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol 2000;53:273-276.
35. Ansari MQ, Zamora JL, Lipscomb MF. Postmortem diagnosis of acute anaphylaxis by serum tryptase analysis. A case report. Am J Clin Pathol 1993;99:101-103
36. Schwartz HJ, Yunginger JW, Schwartz LB. Is unrecognized anaphylaxis a cause of sudden unexpected death? Clin Exp Allergy 1995;25:866-870.
37. Platt MS, Yunginger JW, Sekula-Perlman A, et al. Involvement of mast cells in sudden infant death syndrome. J Allergy Clin Immunol 1994;94:250-256.
38. Randall B, Butts J, Halsey JF. Elevated postmortem tryptase in the absence of anaphylaxis. J Forensic Sci 1995;40:208-211.
39. Edston E, van Hage-Hamsten M. β(beta)-Tryptase measurements post-mortem in anaphylactic deaths and in controls. Forensic Sci Int 1998;93:135-142.
40. Edston E, Gidlund E, Wickman M, et al. Increased mast cell tryptase in sudden infant death-anaphylaxis, hypoxemia or artifact? Clin Exp Allergy 1999;29:1648-1654.
41. Edston E, Eriksson O, van Hage M. Mast cell tryptase in postmortem serum-reference values and confounders. Int J Legal Med 2007;121:275-280.
42. Flower RJ, Harvey EA, Kingston WP. Inflammatory effects of prostaglandin D2 in rat and human skin. Br J Pharmacol 1976;56:229-233.
43. Hardy CC, Robinson C, Tattersfield AE, Holgate ST. The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. N Engl J Med 1984;311:209-213.
44. Pugliese G, Spokas EG, Marcinkiewicz E, Wong PY. Hepatic transformation of prostaglandin D2 to a new prostanoid, 9 alpha,11 beta-prostaglandin F2, that inhibits platelet aggregation and constricts blood vessels. J Biol Chem 1985;260:14621-14625.
45. Goetzl EJ. Oxygenation products of arachidonic acid as mediators of hypersensitivity and inflammation. Med Clin NA 1981; 65:809-828.
46. Raible DG, Schulman ES, DiMuzio J, et al. Mast cell mediators prostaglandin-D2 and histamine activate human eosinophils. J Immunol 1992;148:3536-3542.
47. Juhlin L, Hammarström S. Effects of intradermally injected leukotriene C4 and histamine in patients with urticaria, psoriasis and atopic dermatitis. Br J Dermatol 1982;107 Suppl 23:106-110.
48. Arm JP, Lee TH. Sulphidopeptide leukotrienes in asthma. Clin Sci 1993;84:501-510.
49. Austen KF. The Paul Kallós Memorial Lecture. From slow reacting substance of anaphylaxis to leukotriene C4 synthase. Int Arch Allergy Immunol 1995;107:19-24.
50. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium derived relaxing factor. Nature 1987;327:524-526.
51. Coleman JW. Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. Clin Exp Immunol 2002;129:4-10.
52. Mitsuhata H, Shimizu R, Yokoyama MM. Role of nitric oxide in anaphylactic shock. J Clin Immunol 1995;15:277-283.
53. Rolla G, Nebiolo F, Guida G, et al. Level of exhaled nitric oxide during human anaphylaxis. Ann Allergy Asthma Immunol 2006;97:264-265.
54. Lowenstein CJ, Michel T. What's in a name? eNOS and anaphylactic shock. J Clin Invest 2006;116:2075-2078.
55. Cauwels A, Janssen B, Buys E, et al. Anaphylactic shock depends on PI3K and eNOS-derived NO. J Clin Invest 2006;116:2244-2251.
56. De Souza RL, Short T, Warman GR, et al. Anaphylaxis with associated fibrinolysis, reversed with tranexamic acid and demonstrated by thrombelastography. Anaesth Intensive Care 2004;32:580-587.
57. van der Linden P-WG, Struyvenberg A, Kraaijenhagen RJ, et al. Anaphylactic shock after insect-sting challenge in 138 persons with a previous insect-sting reaction. Ann Intern Med 1993;118:161-168.
58. Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 2002;109:195-209.
59. James LP Jr, Austen KF. Fatal and systemic anaphylaxis in man. N Engl J Med 1964;270:597-603.
60. Warren S, Dixon FJ. Antigen tracer studies and histologic observations in anaphylactic shock in the guinea pig. Part 1. Amer J Med Sci 1948;216:136-145.
61. Lockey RF, Bukantz SC. Allergic emergencies. Med Clin North Am 1974;58:147-156.
62. Munoz J, Bergman RK. Mechanism of anaphylactic death in the mouse. Nature 1965;205:199-200.
63. Coca AF. The mechanism of the anaphylaxis reaction in the rabbit. J Immunol 1919;4:219-231.
64. McCusker HB, Aitken ID. Anaphylaxis in the cat. J Pathol Bacteriol 1966;91:282-285.
65. Greenberger PA, Rotskoff BD, Lifschultz B. Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunol 2007;98:252-257.
66. Trani N, Bonetti LR, Gualandri G, Barbolini G. Immediate anaphylactic death following antibiotics injection: splenic eosinophilia easily revealed by pagoda red stain. Forensic Sci Int 2008;181:21-25.
67. Raper RF, Fisher MM. Profound reversible myocardial depression after anaphylaxis. Lancet 1988;1:386-388.
68. Bristow MR, Ginsburg R, Harrison DC. Histamine and the human heart: the other receptor system. Am J Cardiol 1982;49:249-251.
69. Marone G, Bova M, Detoraki A, et al. The human heart as a shock organ in anaphylaxis. Novartis Found Symp 2004;257:133-149.
70. Wittstein IS, Thiemann DR, Lima JAC, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005;352:539-548.
71. Pumphrey RS. Fatal posture in anaphylactic shock. J Allergy Clin Immunol 2003;112: 451-452.
72. Fisher MM. Clinical observations on the pathophysiology and treatment of anaphylactic cardiovascular collapse. Anaesth Intensive Care 1986;14:17-21.
73. Hermann K, Rittweger R, Ring J. Urinary excretion of angiotensin I, II, arginine vasopressin and oxytocin in patients with anaphylactoid reactions. Clin Exp Allergy 1992;22:845-853.
74. von Tschirschnitz M, von Eschenbach CE, Hermann K, Ring J. Plasma angiotensin II in patients with Hymenoptera venom allergy during hyposensitization [abstract]. J Allergy Clin Immunol 1993;91:283.
75. Hanashiro PK, Weil MH. Anaphylactic shock in man: report of two cases with detailed hemodynamics and metabolic studies. Arch Intern Med 1967;119:129-140.
76. Fahmy NR. Hemodynamics, plasma histamine and catecholamine concentrations during an anaphylactoid reaction to morphine. Anesthesiology 1981;55:329-331.
77. Summers CW, Pumphrey RS, Woods WN, et al. Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center. J Allergy Clin Immunol 2008;121:632-638.
78. Kovanen PT, Kaartinen M, Paavonen T. Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 1995;92:1084-1088.
79. Kounis NG. Kounis syndrome (allergic angina and allergic myocardial infarction): a natural paradigm? Int J Cardiol 2006;110:7-14.
80. Abela GS, Picon PD, Friedl SE, et al. Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model. Circulation 1995;91:776-784.
81. Steffel J, Akhmedov A, Greutert H, et al. Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation 2005;112:341-349.
82. Rubin LE, Levi R. Protective role of bradykinin in cardiac anaphylaxis: coronary-vasodilating and antiarrhythmic activities mediated by autocrine/paracrine mechanisms. Circ Res 1995;76:434-440.
83. Schuligoi R, Amann R, Donnerer J, Peskar BA. Release of calcitonin gene-related peptide in cardiac anaphylaxis. N-S Arch Pharmacol 1997;355:224-229.
84. Rang WQ, Du YH, Hu CP, et al. Protective effects of calcitonin gene-related peptide-mediated evodiamine on guinea-pig cardiac anaphylaxis. N-S Arch Pharmacol 2003;367:306-311.
85. Brown SGA, Blackman KE, Stenlake V, Heddle RJ. Insect sting anaphylaxis: prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. Emerg Med J 2004;21:149-154.
86. Schadt JC, Ludbrook J. Hemodynamic and neurohumoral responses to acute hypovolemia in conscious mammals. Am J Physiol 1991;260:H305-318.
87. Demetriades D, Chan LS, Bhasin P, et al. Relative bradycardia in patients with traumatic hypotension. J Trauma 1998;45:534-539.
88. Szebeni J, Baranyi L, Sávay S, et al. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am J Physiol Heart Circ Physiol 2006;290:H1050-1058.
89. Fink MP. Bench-to-bedside review: cytopathic hypoxia. Crit Care 2002;6:491-499.
90. Dewachter P, Jouan-Hureaux V, Franck P, et al. Anaphylactic shock: a form of distributive shock without inhibition of oxygen consumption. Anesthesiology 2005;103:40-49.